Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Vertex’s Crinetics deal; AstraZeneca’s Phase III fail; J&J’s deal focus; Ipsen's search for rough diamonds; and Dyne’s CEO on strategy.
Scrip - July 14, 2026

Alzheimer’s Blood Tests Equally Accurate In Primary, Secondary Care: Study
New data revealed at AAIC shows blood biomarkers proving their potential to diagnose Alzheimer’s in the sought-after primary care market – and may even have higher accuracy than other tests.
Medtech Insight - July 14, 2026

Federal Appeals Court Clears Plaintiffs’ Experts To Testify In OTC Acetaminophen Class Action
Circuit court decision returns to Southern New York District class action litigation alleging prenatal use of acetaminophen linked to autism and/or attention-deficit hyperactivity disorder in children, allowing testimony from three of six plaintiffs’ expert
HBW Insight - July 14, 2026

Consumers Will Push Back Against AI Reshape Of Beauty Marketing – Mintel
Consumer backlash against AI, demand for multisensory product experiences, and the rise of metabolic health will define the beauty industry through the end of the decade, says Mintel.
HBW Insight - July 14, 2026

Who’s Hired? Sandoz’s Fromm Switches To Accord
As a longtime Sandoz executive switches to Accord Healthcare, new appointments have also been announced at Biosimilars Canada, Medicines For Europe, Stada, Rezon Bio, Pfizer And Pharmanovia.
Generics Bulletin - July 13, 2026

Clean FDA Review Sharpens NRx Ketamine Commercial Case
NRx says FDA reviewers have raised no major issues with its preservative-free ketamine ANDA, as the company prepares for a potential third-quarter decision and continues manufacturing and financing work ahead of launch.
Generics Bulletin - July 13, 2026

Ennumo Approval Gives Accord Two-Pronged Pegfilgrastim Strategy
FDA approval of Ennumo gives Accord a second US pegfilgrastim biosimilar, broadening its G-CSF offering and reinforcing the company’s push to build a 20-product biosimilars portfolio by 2030.
Generics Bulletin - July 13, 2026

Obesity’s Marketing Playbook Is Colliding With Europe’s Advertising Red Lines
France’s ANSM fined Novo Nordisk and Eli Lilly over obesity “awareness” campaigns it says crossed into banned direct-to-consumer promotion. With probes opening across Europe and fines dwarfed by drug revenue, the test is whether enforcement can keep pace with the gold rush.
In Vivo - July 13, 2026